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Lipid structureDepression is one of themost common psychiatric diseases in the population. Agomelatine is a novel antidepres-
sant drug with melatonin receptor agonistic and serotonin 5-HT2C antagonistic properties. Furthermore, being a
melatonergic drug, agomelatine has the potential of being used in therapeutic applications like melatonin as an
antioxidant, anti-inﬂammatory and antiapoptotic drug. The action mechanism of agomelatine on themembrane
structure has not been clariﬁed yet. In the present study, we aimed to investigate the interaction of agomelatine
withmodelmembranes of dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylgylcerol (DPPG)
by Fourier transform infrared (FTIR) spectroscopy and differential scanning calorimetry (DSC). We found that
agomelatine interacts with the head group in such a manner that it destabilizes the membrane architecture to
a large extent. Thus, agomelatine causes alterations in the order, packing and dynamics of the DPPC and DPPG
model membranes. Our results suggest that agomelatine strongly interacts with zwitterionic and chargedmem-
brane phospholipids. Because lipid structure and dynamics may have inﬂuence on the structure of membrane
boundproteins and affect the signal transduction systems ofmembranes, these effects of agomelatinemay be im-
portant in its action mechanism.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Depression is a complex and incapacitating health problem thatmay
represent a signiﬁcant burden to patients, their families and to society
[1]. Drugs related to the uptake process of biogenic amines, e.g. mono-
aminergic antidepressants [tricylics, serotonin reuptake inhibitors
(SSRIs), serotonin noradrenalin reuptake inhibitors (SNRs)] have been
used in the treatment of depression since the middle of the 1950s [2].
However, they do not show their clinical beneﬁt quickly, or do not
even provide any beneﬁt at all for some people. Thus, there is consider-
able interest in new non-monoaminergic approaches for a potentially
effective treatment of depression. Currently, targeting melatonin and
melatonergic receptors has a key role in synchronizing circadian
rhythms, which are known to be disturbed in depressed individuals
[3]. Agomelatine, the ﬁrst melatonergic antidepressant, is a novel drug
and has both agonistic activity on melatonin receptors and antagonistic
activity on serotonine 5-HT2C receptors [4].
Neuronal membrane and neuroplasticity have a key role in the clin-
ical effectiveness and action mechanisms of antidepressant drugs. A
neuroplasticity hypothesis involved in the action mechanism ofantidepressants has gained importance. According to this hypothesis,
membrane connected elements such as receptor binding targets, ion
channels, signal transduction cascades and their interaction with drug
molecules are essential for the action of antidepressant drugs [5,6].
Thus, in order to provide the efﬁcient use of a drug, it is critically impor-
tant to know its site of interaction with membranes at molecular level
[7]. On the other hand, understanding the mechanism of action of the
antidepressant drugs is important to shed an insight to resolve the path-
ogenesis of depression. However, there is limited information in the lit-
erature regarding the interaction of agomelatine with the molecular
components of cells and biological membranes.
Furthermore, being amelatonergic drug, agomelatine has the poten-
tial of being used in therapeutic applications like melatonin as an anti-
oxidant, anti-inﬂammatory and antiapoptotic drug [8–13]. To the best
of our knowledge, the number of studies as to the effect of agomelatine
in this sense is limited [9,14–16].
Biological membranes are complex systems containing lipids,
proteins and carbohydrates. Therefore, model liposomes prepared
from desired membrane components have proven invaluable in mem-
brane research since they mimic biological membranes. The phospho-
lipids used in the liposome formation in the current study have
different polar head groups. It is known that, a difference in the
phospholipid head group causes different intermolecular interactions,
drawing to different packing abilities [17,18]. In our case, the head
group of dipalmitoylphosphatidylcholine (DPPC) is zwitterionic
Fig. 1. FTIR spectra of (A) pure DPPC (…….) and DPPG (——) liposomes in the whole re-
gion, and (B) DPPC and (C) DPPG liposomes containing agomelatine of 0 mol% (…….),
1 mol% (——), and 12 mol% (- - -), in the CH stretching region at 44 °C (spectra were nor-
malized with respect to the CH2 asymmetric stretching band).
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negatively charged.
In biomembrane studies, biophysical techniques such as spectrosco-
py and calorimetry give valuable information on the order–disorder
state, phase transition or thermotropic mesomorphism and provide
information aboutmolecularmotion andmolecularmoieties. Therefore,
this current study aims to investigate the effect of agomelatine on DPPC
and DPPG model membranes. DPPC is one of the main lipids in biologi-
cal membranes. DPPG is chosen as an experimental model lipid since it
is the negatively charged counterpart of DPPC and so is used in order to
understand the effect of charge status in agomelatine–model mem-
brane interactions as reported in other studies [19–21]. To achieve this
aim, different biophysical techniques, namely Fourier transform infra-
red (FTIR) spectroscopy and differential scanning calorimetry (DSC)
have been performed. These techniques provide signiﬁcant and detailed
information about changes in the phase transition behavior, mobility
and structure of individual molecular moieties [19,22–27].
The action mechanism of agomelatine on the membrane structure
has not been clariﬁed yet; for instance, no study has been found in the
literature about the interaction of agomelatinewith the lipids of biolog-
ical membranes. Thus, the main objective of the present study is to
evaluate the interaction of agomelatine with zwitterionic and anionic
membranes DPPC and DPPG at model level, respectively by investigat-
ing structural parameters such as phase transition behavior, lipid
order, strength of hydrogen bonding and functional parameters such
as lipid dynamics. To achieve this, the thermotropic phase transition
proﬁle of the liposomes was compared at different drug concentrations
by FTIR spectroscopy and DSC techniques. To the best of our knowledge,
this is the ﬁrst study to report the interactions of agomelatine with
phospholipid membranes.
2. Results
In the current study, the interactionmechanism of agomelatine at
different concentrations (1–18 mol%) on zwitterionic DPPC and
charged DPPG liposomes in the gel and ﬂuid phases was analyzed
by using FTIR spectroscopy and DSC techniques. For this purpose,
FTIR spectra and DSC thermograms were collected for pure and
agomelatine containing DPPC and DPPG liposomes as a function of
temperature between 20 and 60 °C. Fig. 1A shows the FTIR spectra
of DPPC and DPPG liposomes in the whole region. The CH2 antisym-
metric stretching (~2920 cm−1), CH2 symmetric stretching
(~2850 cm−1), C_O stretching (~1740 cm−1) and PO2− symmetric
stretching (~1080 cm−1) bands were taken into consideration.
Fig. 1B and C shows the normalized FTIR spectra of pure and
agomelatine containing DPPC and DPPG liposomes, respectively in
the C\H stretching region, at a temperature corresponding to the
ﬂuid phase of the membrane to illustrate the alterations induced by
agomelatine. The ﬁgures clearly show that agomelatine induces
changes in the frequency and bandwidth values of the spectral
bands. Since the normalization process does not reﬂect the actual
variations, the detailed spectral changes were performed from the
original subtracted spectra.
The alterations in the frequency values of CH2 antisymmetric and
symmetric stretching vibrations provide information about the mem-
brane phase transition behavior and membrane order [19,22–24,26,
27]. Fig. 2A and B shows the temperature dependent frequency changes
of CH2 symmetric stretching bands of DPPC and DPPG liposomes in the
absence and presence of agomelatine, respectively. As can be seen, there
is an abrupt change in the frequency at ~41 °C for both pure DPPC and
DPPG liposomes. These abrupt changes indicate a transition from gel
to ﬂuid phase where ~41 °C is the main phase transition temperature
(Tm). As it can be inferred from the ﬁgures, agomelatine abolishes the
pre-transition and decreases the main phase transition temperature of
zwitterionic DPPC and charged DPPG liposomes to lower degrees at all
agomelatine concentrations. As seen from Fig. 2A, the addition ofagomelatine to DPPC liposomes causes a downward shift in the
frequency of the CH2 symmetric band in both phases, which corre-
sponds to the ordering effect (i.e. decrease in acyl chain ﬂexibility) of
agomelatine. Contrary, for DPPG liposomes (Fig. 2B), agomelatine
causes a slight increase in the frequency values of the CH2 symmetric
stretching band in both phases indicating a disordering effect (i.e.
increase in acyl chain ﬂexibility).
Fig. 3A and B gives the temperature dependent bandwidth changes
of the CH2 symmetric stretching bands of DPPC and DPPG liposomes
in the absence and presence of agomelatine, respectively. It can be
Fig. 2. Temperature dependent frequency changes of the CH2 symmetric stretching mode
of (A) DPPC liposomes and (B) DPPG liposomes for 0 mol% (♦), 1 mol% (■), 3 mol% (▲),
12 mol% (X) and 18 mol% (*) agomelatine concentrations.
Fig. 3. Temperature dependent bandwidth changes of CH2 symmetric stretching mode of
(A) DPPC liposomes and (B) DPPG liposomes for 0 mol% (♦), 1 mol% (■), 3 mol% (▲),
12 mol% (X) and 18 mol% (*) agomelatine concentrations.
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width implying an increase in the ﬂuidity of both DPPC and DPPG lipo-
somes at all concentrations both in the gel and ﬂuid phases [22–24].
The variations in the frequency of the C_O stretching bandmonitor
the hydration state of glycerol molecules which function as a bridge in
between the phosphate head groups and the acyl chains of the phos-
pholipids [19,22,24,26]. The temperature dependent frequency changes
of the C_O stretching bands of DPPC and DPPG liposomes in the ab-
sence and presence of agomelatine can be seen in Fig. 4A and Fig. 4B, re-
spectively. At a low (1 mol%) agomelatine concentration, the frequency
of this band shifts to higher values, indicating a decrease in the
hydrogen bonding capacity (i.e. dehydration) of the glycerol backbone
of DPPC liposomes (Fig. 4A). In contrast, at higher concentrations of
agomelatine, the enhancement of the hydrogen bonding capacity in
the DPPC liposomes was noticed, which indicates that new H bonds
are formed. In DPPG liposomes, agomelatine decreases the H bonding
capacity of the glycerol backbone, i.e. it increases dehydration, in both
phases except at 18 mol%, for which an increase in H bonding is ob-
served (Fig. 4B). The changes in the frequency of the PO2− symmetric
stretching band give information about the hydration proﬁle of head
groups of phospholipids. A decrement in the frequency of this band cor-
responds to either the strengthening of the existing hydrogen bonds or
formation of new ones [19,22,26,27]. Fig. 4C and D represents the
changes in the PO2− symmetric stretching band frequencies of DPPC
and DPPG liposomes, respectively as a function of temperature. It canbe seen from Fig. 4C that, agomelatine increases the H bonding of the
phosphate head group of DPPC when it is used at high concentrations
(N1 mol%). Moreover agomelatine enhances the H bonding capacity of
the phosphate head group of DPPG liposomes in the gel phase but
lowers it in the ﬂuid phase (Fig. 4D).
Finally, DSC thermograms of pure and agomelatine containing
(1–18 mol%) DPPC and DPPG liposomes can be seen in Fig. 5A and
Fig. 5B, respectively. Tables 1 and 2 give the corresponding phase
transition temperatures (Tm), ΔT1/2 and enthalpy changes of DPPC
and DPPG liposomes, respectively. The small peaks at ~34 °C and
~33 °C of pure DPPC and DPPG liposomes, respectively, are the pre-
transition temperatures. As can be seen, pre-transition disappeared
with the addition of agomelatine. On the other hand, the main
phase transition of pure DPPC and DPPG liposomes are at ~41 °C
and 40 °C with transition enthalpies (ΔH) 40.9 J/g and 42 J/g,
respectively which are consistent with the literature values
[28–30]. The main phase transition shifted to lower temperatures
as the agomelatine concentration is increased. Furthermore,
agomelatine causes a broadening in DSC thermograms of both neu-
tral DPPC and charged DPPG liposomes at all drug concentrations
which indicates loss in cooperativity in the phase transition proﬁle
[23]. Also the system becomes more ﬂuid in the presence of
agomelatine [24]. For concentrations of 12 and 18 mol% two peaks
are clearly observed on the transition curve, implying the existence
Fig. 4. Temperature dependent frequency changes of (A) C_O stretching band of DPPC liposomes and (B) DPPG liposomes; (C) PO2− asymmetric band of DPPC liposomes and (D) DPPG
liposomes for 0 mol% (♦), 1 mol% (■), 3 mol% (▲), 12 mol% (X) and 18% mol (*) agomelatine concentrations.
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formation can be seen better from Fig. 6A and B which shows the
deconvoluted DSC thermograms of DPPC and DPPG liposomes at
18 mol% of agomelatine concentrations, respectively.
3. Discussion
In the current study, interaction of agomelatinewith one of themain
membrane lipids, namely DPPC, and its negatively charged counterpart
DPPG in the form ofMLVs was studied. The usage of DPPC inmembrane
studies is very common [22,24,31,32]. DPPG is also used to understand
the charge effect on drug–membrane interactions [19–21]. Further-
more, there are studies that are concerned with the interaction of anti-
depressants or antipsychotic drugs with DPPG liposomes [20,21,33,34].
Besides, DPPG is one of the model membranes that is used in
Alzheimer's disease [35–37] and Parkinson's disease [38,39] studies.
Alzheimer's disease is characterized by Aβ aggregation and Parkinson's
disease is characterized by α-synuclein aggregation in the brain. These
mentioned studies look for the possible role of membrane lipids in Aβ
and α-synuclein aggregation and state that both Aβ and α-synuclein
bind to negatively charged lipids and use DPPG for this purpose.
Results obtained in the present study extend previous ﬁndings
which demonstrated that agomelatine interacts around the head
group in such a manner that it destabilizes the membrane architecture
to a large extent. Thus, it causes alterations in the order, packing anddynamics of the DPPC and DPPG model membranes. Although
agomelatine was thought to exert its action by interacting only with
melatonin MT1 and MT2, and serotonin 5-HT2C receptors on nerve
cells [4], here in the present study, we demonstrated that agomelatine
has remarkable effects on Tm, acyl chain order, glycerol backbone and
phosphate head groups and on the dynamics of zwitterionic and
charged lipids which reveal that agomelatine interacts also with lipids
in the membrane structure.
It has been reported that the bioactivity of drugs may alter the phys-
ical properties of membranes such as membrane ﬂuidity and formation
of lipid rafts [40] as well as membrane protein–protein and protein–
lipid interactions [41,42]. Therefore, it is important to evaluate or pre-
dict drug–membrane interactions in order to comprehend their action
mechanisms.
The broadening of the phase transition curves imply that
agomelatine enters into the hydrophobic part of the multilamellar bi-
layers and disturb strong van der Waals interactions between the hy-
drophobic acyl chains which causes each phospholipid acyl chain to
melt slightly at a different temperature [23,24]. This shows loss in
cooperativity. The broadening and decrement of Tm suggest that
agomelatine is partially buried in the hydrocarbon core of the bilayer,
interacting primarily with the C2–C8methylene region of the hydrocar-
bon chains [43]. This may lead to the enhancement of interactions be-
tween lipid head groups and/or drug and lipid head groups resulting
with the disturbances of the packing of the system [44,45]. The order–
Fig. 5.DSC thermograms of (A)DPPC liposomeswith andwithout different concentrations
of agomelatine and (B) DPPG liposomes with and without different concentrations of
agomelatine (0 mol% (point), 1 mol% (short dash), 3 mol% (dash), 12 mol% (long dash)
and 18% mol (dash & dot)).
Table 2
Main phase transition temperatures (Tm), full width at half maximum (ΔT1/2) and en-
thalpies of the main phase transitions (ΔH) for DPPG liposomes.
Sample Tm (°C) ΔT1/2 (°C) ΔH (J/g)
DPPG 40.27 2.2 42
DPPG + 1 mol% ago 40.9 3.1 31
DPPG + 3 mol% ago 38.9 4.9 38
DPPG + 12 mol% ago 36.3 – –
DPPG + 18 mol% ago 36.9 – –
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the CH2 symmetric stretching band; a decrease in the frequency
corresponds to an increase in the lipid order (decrease in acyl chain
ﬂexibility) of the system [22,24]. The alterations in the bandwidth of
the C\H stretching bands reﬂect the changes in the dynamics and
hence ﬂuidity of the system [7,22]. The increase of bandwidth indicates
an increase in the ﬂuidity of the system or vice versa. According to the
results of this study, agomelatine enhances the membrane ﬂuidity in
both the gel and ﬂuid phases for all liposomes studied (Fig. 3A and B).
Besides, agomelatine has an ordering effect on zwitterionic DPPC lipo-
somes anddisordering effect on chargedDPPG liposomes in both phases
(Fig. 2A and B). These changes reveal that agomelatine has induced
alterations inmembrane thickness and structure [28,41]. Those changes
may cause disturbances in the selection of certain proteins withTable 1
Main phase transition temperatures (Tm), full width at half maximum (ΔT1/2) and en-
thalpies of the main phase transitions (ΔH) for DPPC liposomes.
Sample Tm (°C) ΔT1/2 (°C) ΔH (J/g)
DPPC 40.8 1.5 40.9
DPPC + 1 mol% ago 40.8 2.3 49.7
DPPC + 3 mol% ago 39.9 4.0 53.6
DPPC + 12 mol% ago 38.4 5.4 56.1
DPPC + 18 mol% ago 37.9 – –optimally adapted trans-membrane segments in biological membranes
[42]. Those disturbances in turn,may lead to impairments inmembrane
fusion and trafﬁcking [45]. Also, controlled membrane ﬂuidity is essen-
tial for the proper functioning of transmembrane receptors such as G
coupled receptors [46].
DSC thermograms (in Fig. 5A and B) clearly showed that the
thermograms broaden as the concentration of agomelatine is increased
for both DPPC and DPPG liposomes. Starting from 12 mol% concentra-
tion of agomelatine for DPPG and at 18 mol% concentration of
agomelatine for DPPC, two peaks are observed in the thermograms.
The deconvolution of DSC thermograms at an 18 mol% concentration
of agomelatine for DPPC and DPPG liposomes gave these peaks in re-
solved form (Fig. 6A and B). These indicate that there is lateral phase
separation into drug-rich and drug-poor domains as observed in other
studies [22,24,47,48]. Domain formation following drug addition may
result in loosely packed lipid bilayers [24,49], which causes alterations
in membrane permeability [50]. Therefore, the loose packing of lipid bi-
layers may innervate the intermolecular interactions [51]. The H bond-
ing differences in the DPPG head groups among the gel and ﬂuid phases
may bedue to the differences in the permeability ofmembranes at these
two phases. In particular, gel phase bilayers are characterized by tight
lipid packing and low permeability, whereas ﬂuid phase analogs are
loosely packed and have relatively high permeability. The highest
permeation rate may happen around Tm where both gel and ﬂuid
phases co-exist. Therefore amismatch can be suggested in lipid packing
between the two phases that produces defects in which permeable
molecules can pass [52].
In addition to temperature changes, gel to ﬂuid phase transition can
also be induced by changes in hydration. Observed progressive de-
creases in Tm with increasing hydration indicates that the adsorption
ofwatermolecules or H atomsdecreases the strength of interactions be-
tween neighboring molecules in the lipid bilayer causing a disturbance
at the polar head group [28]. Alterations at the phosphate head group
may affect acyl chains [44], and the glycerol backbone region modiﬁes
most of the polar/non-polar interfacial parts of the bilayer where the
chemical structure of the interfacial region can inﬂuence the overall
conformation of the lipid molecule [28].
Agomelatine, having a 1H donor and a 2H acceptor site causes alter-
ations in theH bonding capacity of all types of liposomes thatwere used
in the current study. These H bonds might have been formedwith glyc-
erol backbones of adjacent phospholipids and/or with agomelatine [22,
26]. Furthermore, the interaction of agomelatinewith the charged phos-
pholipid DPPG is different from that of zwitterionic DPPC when the H
bonding of the glycerol backbone and the state of order of acyl chains
are considered. One possible reason for this observation could be that
the cationic side chains of the drug may favor electrostatic interactions
with the anionic lipid head group of DPPG, rather than interacting
through hydrophobic interactions with the lipid acyl chain region or
the glycerol backbone.
The main phase transition enthalpy of DPPC liposomes were found
to be increased whereas DPPG liposomes were found to be decreased
from the DSC results (Tables 1 and 2). The different inclinations in the
main phase transition enthalpies of agomelatine–DPPC liposomes and
agomelatine–DPPG liposomes that arose with respect to their pure
Fig. 6. Deconvoluted DSC thermograms of (A) DPPC and (B) DPPG liposomes at 18 mol% of agomelatine concentrations.
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charges of liposomes.
The main phase transition of liposomes is affected mostly from the
van der Waals and trans/gauche rotameric energy [31,53]. In pure
liposomes, an increment in the gauche conformations takes place
which causes the liposomes to gain a rotational mobility during the
main phase transition [54]. However, FTIR spectroscopic results showed
that agomelatine interaction with DPPC liposomes caused the lipids to
go to an ordered state, i.e. less trans/gauche isomerization of fatty acyl
chains and so a reduction in the rotameric energy [31]. This in turn
suggests that, the increment in the enthalpy is not due to the rotational
excitations of fatty acyl chains. Furthermore, as stated, the broadening
of the DSC curve implies that agomelatine interacts with the hydropho-
bic part of the membranes, i.e. fatty acyl chains. Thus, the increase in
enthalpy can be due to the changes in the van derWaals energy as a re-
sult of agomelatine interaction with the hydrophobic part of DPPC lipo-
somes [31,55–59].
As for theDPPG liposomes, itwas found that agomelatine interaction
caused the disordering of liposomes, meaning that the number of
gauche conformers increased (acyl chain ﬂexibility) and this should re-
sult in an increase in the phase transition enthalpy. Thus, agomelatine
might be causing a weakening in the van der Waals interactions due
to strong dipole–dipole interactions and/or changes in the hydration
proﬁle of phosphate head groups that may affect fatty acyl chains as
mentioned above [60]. Furthermore, the reduction in the main phase
transition enthalpy due to agomelatine interaction with DPPG might
also be due to the inhibition of some of the DPPG liposomes to undergo
phase transition [61–64].
It has been reported that agomelatine binds to melatonin receptors,
suppresses cyclic adenosine monophosphate (cAMP) formation and
mimics the actions ofmelatonin in a dose dependentmanner, inhibiting
the ﬁring rate of suprachiasmatic nucleus neurons [4]. These observa-
tions were later substantiated when it was shown that agomelatine
also potently activates cloned human MT1 and MT2 receptors and
mimics melatonin [65]. Regarding the previous studies held in our lab-
oratory, agomelatine exerts the same effects on DPPC liposomes when
compared with melatonin [22]. Both drugs increase the number of
trans conformers and the dynamics of the membrane in the DPPC lipo-
some. However for DPPG liposomes, there are some differences be-
tween the effects of these drugs. For example, melatonin induces
opposite effects on lipid order at high and low concentrations. While
melatonin causes an increase in the order of membranes both in the
gel and ﬂuid phases at low concentrations, it increases the number ofgauche conformers, which indicates a decrease in the order of the bilay-
er at high concentrations [66]. Nonetheless, agomelatine decreases the
lipid order of the DPPG liposome at all phases. Furthermore, in DPPG li-
posomes, melatonin slightly increases the membrane dynamics both in
the gel and ﬂuid phases at high concentrations, but in low concentra-
tions, it decreases the dynamics. However, agomelatine enhances the
membrane ﬂuidity among all types of liposomes studied at all concen-
trations. Finally, both melatonin and agomelatine increase the strength
of H bonding around the phosphate head group for DPPC liposomes. It is
obvious that agomelatine does not show the same effectwithmelatonin
on every liposome type. The reason for this dissimilaritymay be the dif-
ferences between their chemical structures. Melatonin has 2H-bond do-
nors and 2H-bond acceptors whereas agomelatine has a 1H-bonddonor
and 2H-bond acceptors. Besides, these two drugs might have some un-
known different action mechanisms, which may be another reason for
this difference.
Rodrigues et al. (2002) [67] stated that the perturbation of the cell
membrane structure represents an immediate component of the apo-
ptotic pathway in cells, which results in a rapid disruption ofmembrane
lipid polarity and ﬂuidity, altered protein order, and increased oxidative
injury, which precedemetabolic andmorphologicmanifestations of ap-
optosis. Functionally, the increase in plasma membrane ﬂuidity was
found to be associated with the apoptosis of nerve cells [67]. Regarding
our ﬁndings of agomelatine-induced increase in the membrane ﬂuidity
of DPPC andDPPG liposomes, agomelatinemay also play a role in the ac-
tivation of apoptotic pathways in nerve cells.
The molecular organization of the membrane landscape plays an
extremely important role in a great variety of processes associated
with themembrane [68]. Phospholipids weremainly recognized as sec-
ond messengers and their effect on membrane dynamics and structure
was correlated with their role as a host to signaling molecules [69–71].
Except for protein–protein contacts, themembrane-spanning segments
of integral membrane proteins are surrounded by a shell of adjacent
boundary lipids that mediates the coupling between the mostly hydro-
phobic intra-membranous residues of the protein and the lipid bilayer.
In addition to electrostatic interactions, speciﬁc lipid–protein interac-
tions have also been reported. The alterations in the structure of hydro-
phobic regions of the membrane may also inﬂuence both the structure
as well as the function of a number of integral membrane proteins
[46,72]. Since we have observed structural changes in model mem-
branes of all of the phospholipids investigated in this study, these alter-
ations in lipid structure may also affect the protein–lipid interactions in
biological membranes, therefore it can be concluded that agomelatine
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spanningproteins in biologicalmembranes.Membraneﬂuidity is an im-
portant concept for membrane fusion and it is required for membrane
trafﬁcking, regeneration of various sub-cellular compartments after
cell division, and cell growth. Both proteins and lipids have a role in
the regulation of membrane ﬂuidity [45] and a controlled membrane
ﬂuidity is essential for the proper functioning of transmembrane recep-
tors, such as G coupled receptors [73]. Also membrane fusion is a pro-
cess that is regulated by both lipids and proteins [74]. According to the
results of this model lipid membrane study, agomelatine enhances the
membrane ﬂuidity among all types of liposomes studied; therefore,
themembrane fusionmechanismmay be affected following the admin-
istration of agomelatine in biological membranes.
In conclusion, we shed valuable insights into the molecular
mechanisms of the interaction of agomelatine with DPPC and DPPG
MLVs. Our results revealed that agomelatine causes alterations in
the order, packing and dynamics of the DPPC and DPPG model mem-
branes. Changes in the order–disorder state of liposomes were mon-
itored from the CH2 symmetric stretching bands. It was found that
agomelatine causes the ordering of DPPC liposomes, whereas it
causes the disordering of DPPG liposomes in both gel and ﬂuid
phases. The effect of agomelatine on the ﬂuidity of liposomes was
found from the changes in the bandwidth of the CH2 symmetric
stretching bands and an increase in the ﬂuidity of both lipids in
both phases was found. The hydration states of glycerol molecules
and head groups of phospholipids were found by monitoring the fre-
quency of the C_O stretching and the PO2− symmetric stretching
bands, respectively which revealed that, for DPPC liposomes, the H
bonding capacity of the glycerol backbone of both liposomes de-
creases (dehydration) at low concentration (1 mol%) and increases
at higher concentrations in both phases. However for DPPG lipo-
somes, agomelatine generally dehydrates the system in the ﬂuid
phases. In the gel phase, it induces dehydration around the glycerol
backbone, while the H bonding capacity increases around the head
group. DSC studies clearly showed the agomelatine-induced domain
formation for both lipids. Although it has been stated that
agomelatine only interacts with MT1, MT2 and 5-HT2C receptors in
the cell membrane, here in this study, we have demonstrated that
it strongly interacts with membrane phospholipids.
It is known that, lipid structure and dynamics may have an inﬂu-
ence on the structure of membrane bound proteins. Therefore ion
conductivity and cell signaling may be affected following the pertur-
bation of membrane bound proteins. All those results highlight the
fact that agomelatine interact with the head group in such a manner
that it destabilizes the membrane architecture to a large extent. The
overall DSC and FTIR spectroscopic data indicate that agomelatine
induces changes in the structure and psychico-chemical characteris-
tics of the liposomes. This means that agomelatine is able to change
the neuroplasticity of neuronal networks and this statement may
contribute to its clinical effects. Although this idea was supported
by a recent study which demonstrated that agomelatine modulates
the expression of cytoskeletal microtubular proteins, synaptic
markers and brain derived neurotrophic factor (BDNF) in the rat hip-
pocampus, amygdala and prefrontal cortex [75], further studies
should be conducted to speciﬁcally address the effect of agomelatine
on lipid–protein interactions and neuroplasticity.
It is important to understand the action mechanism of a drug to
understand its pharmacologic effect. In the current study, we studied
the general effects of agomelatine on the structure and dynamics of
model membranes obtained from two different lipids in order to see
the charge effect. Since there is no published study yet on this topic,
the information that is derived from this study would be very valuable
as a control study of future studies on the interaction of agomelatine
with other lipid model membranes which, for example, mimic the
brain membranes, and real biological membranes such as liver micro-
somal membranes and brain membranes. However in order to betterunderstand the antidepressant activity and/or other therapeutic effects
of agomelatine in addition to its overall pharmacological effects,
agomelatine-treated healthy and diseased animalmembrane and tissue
studies should be performed for which the results of model membrane
studies would be essential.
4. Materials and methods
4.1. Chemicals
Agomelatine, (N-[2-(7-metoksinaftalen-1-yl)etil]acetamid),
dipalmitoylphosphatidylcholine (DPPC), dipalmitoylphosphatidyl-
glycerol (DPPG) and phosphate buffered saline (PBS) tablets were pur-
chased from Sigma (St. Louis, MO, USA). All chemicals were obtained
from commercial sources at the highest grade of purity available.
4.2. FTIR studies
For FTIR spectroscopic studies, multilamellar vesicles (MLVs) were
prepared in the absence and the presence of 1, 3, 12 and 18 mol%
agomelatine according to the procedure reported in [22,49]. Brieﬂy, 5
mg of DPPC and DPPG were separately dissolved in 150 μl chloroform
in tubes and the solution was subjected to a stream of nitrogen to
remove excess chloroform followed by vacuum drying for 2 h. Subse-
quently, a dry ﬁlm was obtained. Thin ﬁlms of lipids were hydrated by
adding 25 μl of PBS buffer solution, pH 7.4. MLVs were formed by
vortexing the mixture for 20 min at a temperature of 20 °C above the
main transition temperature of lipids. To prepare agomelatine contain-
ing MLVs, the appropriate amount of agomelatine from stock solution
(2.5 mg/ml) was initially placed inside the sample tube. Excess ethanol
was removed by a stream of nitrogen, then the phospholipid was added
and MLVs were prepared as described above.
The PBS solution that we used during the experiments was obtained
by dissolving the PBS tablets in deionized water. This buffer was also
used in other MLV studies [76–78]. This results in a solution of 0.01 M
phosphate buffer with 0.0027 M potassium chloride and 0.137 M sodi-
um chloridewith a pH level of 7.4. The resultant ionic strength of the so-
lution is 162.7 mM. This results in a Debye length, i.e. the screening
length of charges that are in solutions with salts, of 0.76 nm at 300 K
[29,79]. Such a Debye length has the same order of magnitude as the
lipid–lipid spacing of MLVs [80].
For FTIR spectroscopic data collection, 20 μl of liposomes was placed
between CaF2 windows with a 12 μl spacer to obtain consistent sample
thickness. Spectra were recorded using a Perkin Elmer Spectrum 100
FTIR spectrometer (Perkin Elmer, Inc., Norwalk, CT, USA) equipped
with a deuterated triglycine sulfate (DTGS) detector, in the temperature
range of 20–60 °C. Temperature was controlled digitally by a Graseby
Specac controller unit. Samples were incubated for 5 min at each tem-
perature before the acquisition of a spectrum. Interferograms were av-
eraged for 100 scans at 2 cm−1 resolution. The spectrum of the air
was recorded as a background spectrum and subtracted automatically
from the spectra of samples by using the Perkin Elmer Spectrum One
software, which was also used for data analyses.
Since theOH stretching bands due to the buffer appear in the regions
of 3400–3200 cm−1 and 1800–1500 cm−1, these bands overlap with
the bands of interest. Therefore, the spectrum of the buffer was taken
at different temperatures andwas subtracted from the spectrumof lipo-
somes at corresponding temperatures. The subtraction processwas per-
formed till the bulk water region located around 2100 cm−1 was
ﬂattened using the Perkin Elmer software program.
For the determination of variations in peak positions and band-
widths, each original spectrum was analyzed by using the same soft-
ware. The band positions and bandwidths were measured from the
center of weight (0.80× peak height position), respectively. The
detailed analyses were performed from the subtracted native spectra.
2805S. Ergun et al. / Biochimica et Biophysica Acta 1838 (2014) 2798–2806However, for visual demonstration of the spectral differences in the
spectra, the spectra were normalized with respect to the speciﬁc bands.
4.3. DSC studies
For calorimetric studies, MLVswere prepared in the absence and the
presence of 1, 3, 12, and 18 mol% agomelatine. For the preparation of
MLVs, thin ﬁlms containing 2 mg lipid were hydrated by adding 50 μl
of PBS buffer solution, pH 7.4, and the procedure mentioned above
was followed. 50 μl MLV suspensionswere encapsulated in hermetically
sealed standard aluminum DSC pans. An indium containing pan was
used as reference during the analysis.
Investigation was performed with a Universal TA DSC Q100 v 6.21
instrument. The scans were collected at 1 °C/min. Only heating curves
are presented. Cooling curves were essentially identical. The enthalpy
(ΔH° cal) values were calculated by calculating the area under main
transition.
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